Prelude Therapeutics Total Cash From Financing Activities Over Time
| PRLD Stock | USD 1.05 0.07 7.14% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Prelude Therapeutics Performance and Prelude Therapeutics Correlation. Prelude |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.77) | Revenue Per Share 0.04 | Return On Assets (0.39) | Return On Equity (0.67) |
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Cash From Financing Activities Analysis
Compare Prelude Therapeutics and related stocks such as Foghorn Therapeutics, Shattuck Labs, and Monte Rosa Therapeutics Total Cash From Financing Activities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FHTX | 51.8 M | 51.8 M | 51.8 M | 51.8 M | 51.8 M | 51.8 M | 51.8 M | 51.8 M | 51.8 M | 24 M | 217.5 M | 22.4 M | 1.8 M | 1.8 M | 1.7 M |
| STTK | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | (64 K) | 330.9 M | 1.9 M | 171 K | 48.6 M | 55.6 M |
| GLUE | 15 M | 15 M | 15 M | 15 M | 15 M | 15 M | 15 M | 15 M | 15 M | 15 M | 60.1 M | 377.6 M | 20.5 M | 27.5 M | 26.1 M |
| KYMR | 52.9 M | 52.9 M | 52.9 M | 52.9 M | 52.9 M | 52.9 M | 52.9 M | 52.9 M | 52.9 M | 34.9 M | 289.3 M | 250.3 M | 153 M | 4.2 M | 4 M |
| NRIX | 529 K | 529 K | 529 K | 529 K | 529 K | 529 K | 529 K | 529 K | 126 K | 339 M | 153.9 M | 117.2 M | 3.2 M | 3.7 M | 3.5 M |
| CCCC | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 244 K | 348.9 M | 171.4 M | 1.1 M | 45.5 M | 43.2 M |
| ELYM | 26.2 M | 26.2 M | 26.2 M | 26.2 M | 26.2 M | 26.2 M | 26.2 M | 26.2 M | 26.2 M | 26.2 M | 4.9 M | 177.2 M | 38 K | 841 K | 799 K |
| RZLT | 10.5 K | 10.5 K | 1.4 M | 9.9 M | 10 M | 10.7 M | 13.9 M | 9.5 M | 25 M | 22.6 M | 51.5 M | 149 M | 11.6 M | 63 M | 32 M |
| MOLN | (2 M) | (2 M) | (2 M) | (2 M) | 101.2 M | 229.2 K | 395 K | 799 K | 392 K | (227 K) | 113.2 M | 50.6 M | (1.6 M) | (1.2 M) | (1.1 M) |
| MLYS | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 23.8 M | 128 M | 203.2 M | 213.4 M |
| ANTX | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 3.8 M | 78.5 M | 70.4 M | 85 M | 54.1 M |
| PHVS | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 21.6 M | 101.2 M | 143.7 M | 8.7 M | 325.4 M | 341.7 M |
| PEPG | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 8 M | 147.7 M | 112.2 K | (189 K) | (179.6 K) |
| RVMD | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 60.8 M | 98.7 M | 422.8 M | 294.2 M | 301.4 M | 1.2 B | 1.3 B |
| BDTX | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 52.3 M | 127.8 M | 214.9 M | 729 K | 177 K | 71.9 M | 54.6 M |
| PASG | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 175.6 M | 228.8 M | 166.7 K | (1.4 K) | 135 K | 128.2 K |
Prelude Therapeutics and related stocks such as Foghorn Therapeutics, Shattuck Labs, and Monte Rosa Therapeutics Total Cash From Financing Activities description
My Equities
My Current Equities and Potential Positions
| Prelude Therapeutics | PRLD |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Delaware; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.05
Check out Prelude Therapeutics Performance and Prelude Therapeutics Correlation. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Prelude Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.